WO2001072830A2 - Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion - Google Patents
Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion Download PDFInfo
- Publication number
- WO2001072830A2 WO2001072830A2 PCT/EP2001/003708 EP0103708W WO0172830A2 WO 2001072830 A2 WO2001072830 A2 WO 2001072830A2 EP 0103708 W EP0103708 W EP 0103708W WO 0172830 A2 WO0172830 A2 WO 0172830A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chemokine receptor
- receptors
- chemokine
- antibodies
- different
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- X represents an amino acid residue or a peptide residue of up to 30 amino acids
- Y represents an amino acid residue or a peptide residue of up to 30 amino acids
- nude mice Since nude mice have a deficient immune system, the metastatic behavior in a host body can be examined in a nude mouse model without the known immune reactions between species taking place and the foreign cells being rejected. Nude mice are vaccinated in a manner known per se with tumor cells or tumor cell lines whose chemokine receptor distribution pattern had been analyzed and the metastasis by these cells is checked when treated with chemokines and when treated with chemokine antagonists and / or receptor antibodies. Surprisingly, it is found that chemokine antagonists and receptor antibodies belonging to the found receptors significantly inhibit or prevent metastasis, while the addition of chemokines leads to a modulation of tumor growth. Surprisingly, it also emerges that the preparations analyzed by immunohistochemistry show a specific distribution of chemokines and chemokine receptors in the tumor and surrounding tissue. This identified additional targeted intervention options.
- chemokine / chemokine receptor proteome in particular the chemokine receptors CXCR4, and CCR5 and / or CXCR3, can also be used in the rejection of Kidney transplants can be demonstrated.
- chemokine receptors CXCR4, and CCR5 and / or CXCR3 can also be used in the rejection of Kidney transplants.
- In vitro experiments have also shown that a mixture of antibodies and antagonists directed at these receptors strongly inhibits the migration of disease-specific effector cells.
- chemokine receptors preferably CCR and CXCR
- other clusters of the tumor cell surface proteome preferably CCR and CXCR
- mice type NZW X NZB
- the mice are used to produce monoclonal antibodies, which is carried out using the routine methods of IPF PharmaCeuticals GmbH.
- the antibodies checked by Western blot and ELISA can be used for the above-mentioned diagnostic and therapeutic purposes if they are highly purified using the laboratory methods of IPF PharmaCeuticals GmbH.
- the sequences used for the chemokine receptors must be selected in accordance with sequence ID 1-63.
- the tumor cells could be obtained and analyzed by immunohistochemical methods and other molecular biological methods.
- the primary tumor cells, the metastases and circulating single cells contain a specific composition of chemokines and chemokine receptors.
- the algorithm of this composition is individually and tumor-dependent of high specificity, which surprisingly enables targeted tumor treatment based on the diagnosed proteome clusters using the method according to the invention.
- the algorithms of the chemokine receptors are preferably suitable here. According to the invention, these algorithms derived from the tests are defined as follows:
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01923710A EP1268554A2 (de) | 2000-03-31 | 2001-04-02 | Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion |
JP2001571761A JP2003530325A (ja) | 2000-03-31 | 2001-04-02 | 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター/リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤 |
AU2001250412A AU2001250412A1 (en) | 2000-03-31 | 2001-04-02 | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10016013 | 2000-03-31 | ||
DE10016013.1 | 2000-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001072830A2 true WO2001072830A2 (de) | 2001-10-04 |
WO2001072830A3 WO2001072830A3 (de) | 2002-06-20 |
Family
ID=7637100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/003708 WO2001072830A2 (de) | 2000-03-31 | 2001-04-02 | Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030186889A1 (de) |
EP (1) | EP1268554A2 (de) |
JP (1) | JP2003530325A (de) |
AU (1) | AU2001250412A1 (de) |
WO (1) | WO2001072830A2 (de) |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100383529B1 (en) * | 2002-04-08 | 2003-05-12 | Biolnfra Inc | Method and system for analysis of cancer biomarker using proteome image mining |
WO2003102589A1 (en) * | 2002-04-08 | 2003-12-11 | Bioinfra Inc. | Method and system for analysis of cancer biomarkers using proteome image mining |
WO2004019046A1 (en) * | 2002-08-19 | 2004-03-04 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6) |
WO2004074321A2 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
EP1698902A1 (de) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Verwendung von XCR1 zur Diagnose und Überwachung der Immuntoleranz |
EP2260858A2 (de) | 2003-11-06 | 2010-12-15 | Seattle Genetics, Inc. | Monomethylvalinverbindungen mit Ligandenkonjugationsfähigkeit |
EP2286844A2 (de) | 2004-06-01 | 2011-02-23 | Genentech, Inc. | Antikörper-Arzneimittelkonjugate und Verfahren |
WO2011031870A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
WO2011056983A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2012000906A1 (en) * | 2010-06-28 | 2012-01-05 | Universitätsklinikum Freiburg | Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer |
WO2012062713A1 (en) * | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
US8263064B2 (en) | 2007-06-04 | 2012-09-11 | Rappaport Family Institute For Research In The Medical Sciences | Method of suppressing disease severity of multiple sclerosis using chemokine CXC11 |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015023355A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015095212A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2016040856A2 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
EP3088004A1 (de) | 2004-09-23 | 2016-11-02 | Genentech, Inc. | Cystein-manipulierte antikörper und konjugate |
WO2017059289A1 (en) | 2015-10-02 | 2017-04-06 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
WO2017064675A1 (en) | 2015-10-16 | 2017-04-20 | Genentech, Inc. | Hindered disulfide drug conjugates |
WO2017068511A1 (en) | 2015-10-20 | 2017-04-27 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
EP3235820A1 (de) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepine und antikörper-disulfid-konjugate davon |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2019060398A1 (en) | 2017-09-20 | 2019-03-28 | Ph Pharma Co., Ltd. | ANALOGUES OF THAILANSTATINE |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
WO2020049286A1 (en) | 2018-09-03 | 2020-03-12 | Femtogenix Limited | Polycyclic amides as cytotoxic agents |
WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2020157491A1 (en) | 2019-01-29 | 2020-08-06 | Femtogenix Limited | G-a crosslinking cytotoxic agents |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2022023735A1 (en) | 2020-07-28 | 2022-02-03 | Femtogenix Limited | Cytotoxic agents |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11427640B1 (en) | 2020-06-26 | 2022-08-30 | Bayer Aktiengesellschaft | CCR8 antibodies for therapeutic applications |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE347594T1 (de) * | 1994-01-13 | 2006-12-15 | Univ California | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
EP1569510B1 (de) | 2002-09-27 | 2011-11-02 | The General Hospital Corporation | Mikrofluidische vorrichtung zur zelltrennung und verwendungen davon |
JP4452839B2 (ja) * | 2004-03-09 | 2010-04-21 | 国立大学法人京都大学 | Cxcr3阻害剤を含有する医薬組成物 |
CA2501422C (en) * | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
US20090054322A1 (en) * | 2005-05-26 | 2009-02-26 | Rappaport Family Institute For Research In The Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
CA3009680C (en) | 2006-03-16 | 2023-08-15 | Symthera Canada Ltd. | Combination of cytokine and cytokine receptor for altering immune system functioning |
US7879799B2 (en) * | 2006-08-10 | 2011-02-01 | Institute For Systems Biology | Methods for characterizing glycoproteins and generating antibodies for same |
US20100227824A1 (en) * | 2008-10-10 | 2010-09-09 | Chai Ezerzer | Pharmaceutical peptides for the treatment of inflammatory diseases |
CN103347896B (zh) | 2010-09-02 | 2017-06-13 | 瓦西尼斯公司 | 抗cxcl13抗体和其使用方法 |
US9371389B2 (en) * | 2011-09-01 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Anti-human XCR1 antibodies |
JP6193275B2 (ja) | 2012-03-02 | 2017-09-06 | ヴァクシネックス, インコーポレイテッド | B細胞媒介炎症性疾患を治療するための方法 |
CN104884087B (zh) * | 2012-09-06 | 2019-07-30 | 阿德莱德研究创新有限公司 | 预防和/或治疗转移性癌症的产品和方法 |
CA2894961C (en) | 2012-12-21 | 2020-09-15 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
CN105246894A (zh) | 2012-12-21 | 2016-01-13 | 斯皮罗根有限公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
AU2014212206B2 (en) | 2013-01-31 | 2018-10-18 | Vaccinex, Inc. | Methods for increasing immunoglobulin A levels |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240975A2 (de) * | 1986-04-08 | 1987-10-14 | Yeda Research And Development Company Limited | Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen |
WO1995007934A2 (en) * | 1993-09-14 | 1995-03-23 | Chiron Corporation | Il8 inhibitors |
WO1996009062A1 (en) * | 1994-09-23 | 1996-03-28 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
WO1998006398A1 (en) * | 1996-08-15 | 1998-02-19 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
WO2000000515A2 (en) * | 1998-06-29 | 2000-01-06 | Hyseq, Inc. | A CHEMOKINE RECEPTOR OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN |
-
2001
- 2001-04-02 US US10/239,423 patent/US20030186889A1/en not_active Abandoned
- 2001-04-02 EP EP01923710A patent/EP1268554A2/de not_active Withdrawn
- 2001-04-02 AU AU2001250412A patent/AU2001250412A1/en not_active Abandoned
- 2001-04-02 JP JP2001571761A patent/JP2003530325A/ja active Pending
- 2001-04-02 WO PCT/EP2001/003708 patent/WO2001072830A2/de not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240975A2 (de) * | 1986-04-08 | 1987-10-14 | Yeda Research And Development Company Limited | Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen |
WO1995007934A2 (en) * | 1993-09-14 | 1995-03-23 | Chiron Corporation | Il8 inhibitors |
WO1996009062A1 (en) * | 1994-09-23 | 1996-03-28 | University Of Nebraska Board Of Regents | Polypeptide agonists and antagonists of human interleukin-8 |
WO1998006398A1 (en) * | 1996-08-15 | 1998-02-19 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
WO2000000515A2 (en) * | 1998-06-29 | 2000-01-06 | Hyseq, Inc. | A CHEMOKINE RECEPTOR OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN |
Non-Patent Citations (1)
Title |
---|
LEHNER T ET AL: "INDUCTION OF INHIBITORY ANTIBODIES TO THE CCR5 CHEMOKINE RECEPTOR AND THEIR COMPLEMENTARY ROLE IN PREVENTING SIV INFECTION IN MACAQUES" EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, Bd. 29, August 1999 (1999-08), Seiten 2427-2435, XP000985910 ISSN: 0014-2980 * |
Cited By (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003102589A1 (en) * | 2002-04-08 | 2003-12-11 | Bioinfra Inc. | Method and system for analysis of cancer biomarkers using proteome image mining |
KR100383529B1 (en) * | 2002-04-08 | 2003-05-12 | Biolnfra Inc | Method and system for analysis of cancer biomarker using proteome image mining |
WO2004019046A1 (en) * | 2002-08-19 | 2004-03-04 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 6(cxcr6) |
EP2058408A3 (de) * | 2003-02-14 | 2009-09-09 | Sagres Discovery, Inc. | Therapeutische GPCR-Targets für Karzinome |
WO2004074321A2 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
WO2004074321A3 (en) * | 2003-02-14 | 2005-01-13 | Sagres Discovery Inc | Therapeutic gpcr targets in cancer |
EP3858387A1 (de) | 2003-11-06 | 2021-08-04 | Seagen Inc. | Zur konjugierung an liganden fähige monomethylvalinverbindungen |
EP3120861A1 (de) | 2003-11-06 | 2017-01-25 | Seattle Genetics, Inc. | Zwischenverbindungen zur herstellung von konjugaten von auristatinderivaten mit linkern |
EP2260858A2 (de) | 2003-11-06 | 2010-12-15 | Seattle Genetics, Inc. | Monomethylvalinverbindungen mit Ligandenkonjugationsfähigkeit |
EP2489364A1 (de) | 2003-11-06 | 2012-08-22 | Seattle Genetics, Inc. | Mit Antikörpern konjugierte onomethylvalinverbindungen |
EP2486933A1 (de) | 2003-11-06 | 2012-08-15 | Seattle Genetics, Inc. | Mit Antikörpern konjugierte Monomethylvalinverbindungen |
EP2478912A1 (de) | 2003-11-06 | 2012-07-25 | Seattle Genetics, Inc. | Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung |
EP3434275A1 (de) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Auf die verwendung von auristatin-konjugaten mit antikörpern basierter nachweis für krebszellen |
EP2286844A2 (de) | 2004-06-01 | 2011-02-23 | Genentech, Inc. | Antikörper-Arzneimittelkonjugate und Verfahren |
EP3088004A1 (de) | 2004-09-23 | 2016-11-02 | Genentech, Inc. | Cystein-manipulierte antikörper und konjugate |
WO2006092385A2 (en) * | 2005-03-01 | 2006-09-08 | Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Use of xcr1 for diagnosing or monitoring of immune tolerance |
WO2006092385A3 (en) * | 2005-03-01 | 2007-03-22 | Dkfz Krebsforschungszentrum | Use of xcr1 for diagnosing or monitoring of immune tolerance |
EP1698902A1 (de) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Verwendung von XCR1 zur Diagnose und Überwachung der Immuntoleranz |
US8263064B2 (en) | 2007-06-04 | 2012-09-11 | Rappaport Family Institute For Research In The Medical Sciences | Method of suppressing disease severity of multiple sclerosis using chemokine CXC11 |
WO2011031870A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
WO2011056983A1 (en) | 2009-11-05 | 2011-05-12 | Genentech, Inc. | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
WO2011130598A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2011156328A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2012000906A1 (en) * | 2010-06-28 | 2012-01-05 | Universitätsklinikum Freiburg | Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer |
US10786550B2 (en) | 2010-06-28 | 2020-09-29 | Universitatsklinikum Freiburg | Blockade of CCL18 signaling via CCR6 as a therapeutic option in treating interstitial lung disease |
AU2018275016B2 (en) * | 2010-11-08 | 2020-07-09 | Ablynx N.V. | CXCR2 binding polypeptides |
EP3578568A3 (de) * | 2010-11-08 | 2020-01-08 | Ablynx N.V. | Cxcr2-bindende polypeptide |
WO2012062713A1 (en) * | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
KR101650995B1 (ko) * | 2010-11-08 | 2016-08-25 | 노파르티스 아게 | Cxcr2 결합 폴리펩티드 |
KR20130108414A (ko) * | 2010-11-08 | 2013-10-02 | 노파르티스 아게 | Cxcr2 결합 폴리펩티드 |
EA037063B1 (ru) * | 2010-11-08 | 2021-02-01 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
AU2011328246B2 (en) * | 2010-11-08 | 2016-06-30 | Ablynx N.V. | CXCR2 binding polypeptides |
AU2011328246A1 (en) * | 2010-11-08 | 2013-05-23 | Ablynx N.V. | CXCR2 binding polypeptides |
KR101832040B1 (ko) | 2010-11-08 | 2018-04-04 | 노파르티스 아게 | Cxcr2 결합 폴리펩티드 |
US8591896B2 (en) | 2010-11-08 | 2013-11-26 | Novartis Ag | Chemokine receptor binding polypeptides |
EP3575321A1 (de) * | 2010-11-08 | 2019-12-04 | Ablynx N.V. | Cxcr2 bindende polypeptide |
US9127067B2 (en) | 2010-11-08 | 2015-09-08 | Novartis Ag | Methods of treatment using chemokine receptor binding polypeptides |
US10174118B2 (en) | 2010-11-08 | 2019-01-08 | Novartis Ag | Nucleic acids encoding chemokine receptor binding polypeptides |
WO2012074757A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
US11135303B2 (en) | 2011-10-14 | 2021-10-05 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
US9688763B2 (en) | 2012-05-09 | 2017-06-27 | Novartis Ag | Chemokine receptor binding polypeptides |
US11466089B2 (en) | 2012-05-09 | 2022-10-11 | Ablynx N.V. | Chemokine receptor binding polypeptides |
US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
US10994023B2 (en) | 2012-10-12 | 2021-05-04 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11779650B2 (en) | 2012-10-12 | 2023-10-10 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11771775B2 (en) | 2012-10-12 | 2023-10-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11701430B2 (en) | 2012-10-12 | 2023-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US11690918B2 (en) | 2012-10-12 | 2023-07-04 | Medimmune Limited | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
WO2014057074A1 (en) | 2012-10-12 | 2014-04-17 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
US10646584B2 (en) | 2012-10-12 | 2020-05-12 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
US9889207B2 (en) | 2012-10-12 | 2018-02-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US10335497B2 (en) | 2012-10-12 | 2019-07-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9919056B2 (en) | 2012-10-12 | 2018-03-20 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US9931415B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10799596B2 (en) | 2012-10-12 | 2020-10-13 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-antibody conjugates |
US10722594B2 (en) | 2012-10-12 | 2020-07-28 | Adc Therapeutics S.A. | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
US10780181B2 (en) | 2012-10-12 | 2020-09-22 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
EP2839860A1 (de) | 2012-10-12 | 2015-02-25 | Spirogen Sàrl | Pyrrolobenzodiazepine und Konjugate davon |
WO2014159981A2 (en) | 2013-03-13 | 2014-10-02 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140862A2 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014140174A1 (en) | 2013-03-13 | 2014-09-18 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
WO2015023355A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
US10029018B2 (en) | 2013-10-11 | 2018-07-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
US9950078B2 (en) | 2013-10-11 | 2018-04-24 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
WO2015095212A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
WO2016040856A2 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
US10420777B2 (en) | 2014-09-12 | 2019-09-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
EP3235820A1 (de) | 2014-09-17 | 2017-10-25 | Genentech, Inc. | Pyrrolobenzodiazepine und antikörper-disulfid-konjugate davon |
US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
US11702473B2 (en) | 2015-04-15 | 2023-07-18 | Medimmune Limited | Site-specific antibody-drug conjugates |
US11059893B2 (en) | 2015-04-15 | 2021-07-13 | Bergenbio Asa | Humanized anti-AXL antibodies |
WO2017059289A1 (en) | 2015-10-02 | 2017-04-06 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
WO2017064675A1 (en) | 2015-10-16 | 2017-04-20 | Genentech, Inc. | Hindered disulfide drug conjugates |
WO2017068511A1 (en) | 2015-10-20 | 2017-04-27 | Genentech, Inc. | Calicheamicin-antibody-drug conjugates and methods of use |
US10392393B2 (en) | 2016-01-26 | 2019-08-27 | Medimmune Limited | Pyrrolobenzodiazepines |
US11517626B2 (en) | 2016-02-10 | 2022-12-06 | Medimmune Limited | Pyrrolobenzodiazepine antibody conjugates |
US10695439B2 (en) | 2016-02-10 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2017165734A1 (en) | 2016-03-25 | 2017-09-28 | Genentech, Inc. | Multiplexed total antibody and antibody-conjugated drug quantification assay |
EP4273551A2 (de) | 2016-03-25 | 2023-11-08 | F. Hoffmann-La Roche AG | Multiplex-gesamtantikörper- und antikörper-konjugierter arzneimittelquantifizierungstest |
US10543279B2 (en) | 2016-04-29 | 2020-01-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer |
WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
WO2018065501A1 (en) | 2016-10-05 | 2018-04-12 | F. Hoffmann-La Roche Ag | Methods for preparing antibody drug conjugates |
US10799595B2 (en) | 2016-10-14 | 2020-10-13 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US11612665B2 (en) | 2017-02-08 | 2023-03-28 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US11813335B2 (en) | 2017-02-08 | 2023-11-14 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
US11370801B2 (en) | 2017-04-18 | 2022-06-28 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
US10544223B2 (en) | 2017-04-20 | 2020-01-28 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
US11938192B2 (en) | 2017-06-14 | 2024-03-26 | Medimmune Limited | Dosage regimes for the administration of an anti-CD19 ADC |
US11318211B2 (en) | 2017-06-14 | 2022-05-03 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-CD19 ADC |
US11649250B2 (en) | 2017-08-18 | 2023-05-16 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
WO2019060398A1 (en) | 2017-09-20 | 2019-03-28 | Ph Pharma Co., Ltd. | ANALOGUES OF THAILANSTATINE |
US11352324B2 (en) | 2018-03-01 | 2022-06-07 | Medimmune Limited | Methods |
US11524969B2 (en) | 2018-04-12 | 2022-12-13 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents |
WO2020049286A1 (en) | 2018-09-03 | 2020-03-12 | Femtogenix Limited | Polycyclic amides as cytotoxic agents |
WO2020086858A1 (en) | 2018-10-24 | 2020-04-30 | Genentech, Inc. | Conjugated chemical inducers of degradation and methods of use |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
WO2020157491A1 (en) | 2019-01-29 | 2020-08-06 | Femtogenix Limited | G-a crosslinking cytotoxic agents |
US11427640B1 (en) | 2020-06-26 | 2022-08-30 | Bayer Aktiengesellschaft | CCR8 antibodies for therapeutic applications |
WO2022023735A1 (en) | 2020-07-28 | 2022-02-03 | Femtogenix Limited | Cytotoxic agents |
Also Published As
Publication number | Publication date |
---|---|
WO2001072830A3 (de) | 2002-06-20 |
AU2001250412A1 (en) | 2001-10-08 |
EP1268554A2 (de) | 2003-01-02 |
JP2003530325A (ja) | 2003-10-14 |
US20030186889A1 (en) | 2003-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001072830A2 (de) | Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion | |
DE69628652T2 (de) | Vegf-verwandtes protein | |
DE69936315T2 (de) | Fragmente des wachstumsfaktors für bindegewebe (ctgf) und verfahren und anwendungen davon | |
DE69635565T2 (de) | Antagonisten des vaskulären Endothelzellen-Wachstumfaktors | |
DE69914463T2 (de) | Therapeutische chemokine rezeptor antagonisten | |
DE69729125T2 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
DE69926536T2 (de) | Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung | |
JP3115561B2 (ja) | 白血球を増加させるための医薬組成物の製造方法 | |
DE69934425T2 (de) | Thrombopoietin substitute | |
DE69532767T2 (de) | Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III | |
DE69727558T2 (de) | Humanes CYR61, ein Signalmolekül der extrazellularen Matrix | |
DE69724451T2 (de) | Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen | |
DE69233441T2 (de) | Menschliches Zelloberflächen-Antigen codierende DNA | |
EP0167575B2 (de) | Cardiodilatin, neues peptidhormon und verfahren zu seiner herstellung | |
DE69635675T2 (de) | Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor | |
DE69433648T2 (de) | Menschliche chemokin-polypeptide | |
DE60217326T2 (de) | Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung | |
DE69728529T2 (de) | Cytokinantagonisten und -agonisten | |
DE69532436T2 (de) | Einzelkettenformen des clycoprotein-hormon-quartetts | |
DE69734141T2 (de) | PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER | |
DE69931482T2 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
DE60207043T2 (de) | Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese | |
EP0736095B1 (de) | Humanes zirkulierendes cytokin cc-1 | |
EP1644028B1 (de) | Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen | |
DE69920405T2 (de) | Verwendung des heregulins als epithelzellenwachstumsfaktor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10239423 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001923710 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 571761 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2001923710 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001923710 Country of ref document: EP |